Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Next Previous
Trial Profile

An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Incyte Corporation

Most Recent Events

  • 18 Apr 2022 Results (as of 8 May 2020; n=60) assessing safety of ruxolitinib, data on serious adverse events (SAEs) reported among patients in the EAP were collected, published in the Bone Marrow Transplantation.
  • 01 Dec 2021 Status changed from recruiting to completed.
  • 08 Dec 2020 Results reporting safety data from patients with steroid-refractory chronic GVHD who received Ruxolitinib in this Incyte-sponsored US EAP, were presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top